CMIC Co, Ltd. Japan   Report issue

For profit Phase 2 Phase 3
Founded: Tokyo Japan (1992)

Organization Overview

First Clinical Trial
2008
NCT01194804
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

CMIC Co, Ltd. Japan

Active Ingredients

Drugs in Phase 3 Trials (3)

calcipotriene (dovonex) (1 trial)

leo 80185 (1 trial)

mirogabalin (2 trials)

Drugs in Phase 2 Trials (1)

eculizumab (Soliris) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 3)

Hemoglobinuria (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 2)

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Psoriasis (Phase 3)

Renal Insufficiency (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4